An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)

Dane, F.Ozgurdal, K.Yalcin, S.Benekli, M.Aykan, N. F.Yucel, I.Ozkan, M.Evrensel, T.Sevinc, A.Coskun, H. S.Sanli, U. S.Kara, I. O.2019-10-272019-10-2720150923-75341569-8041https://doi.org/10.1093/annonc/mdv233.253https://hdl.handle.net/11454/42136ESMO 17th World Congress on Gastrointestinal Cancer -- JUL 01-04, 2015 -- Barcelona, SPAINen10.1093/annonc/mdv233.253info:eu-repo/semantics/openAccessAn open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)Conference Object26WOS:000357047400123Q1